MiniMed hits a record as guidance hike follows first stand-alone quarter
A fiscal first-quarter sales beat sent MiniMed (MMED) to a record high Tuesday, and the company followed by raising its full-year guidance. The quarter was MiniMed's first as an independent public company after the spinoff from Medtronic (MDT) closed in March, giving the tape its earliest read on how the diabetes device business performs outside the parent's structure.
Key takeaways
- MiniMed (MMED) hit a record high Tuesday after a fiscal first-quarter sales beat, and the company raised its full-year guidance.
- The quarter was MiniMed's first as an independent public company following its spinoff from Medtronic, which closed in March.
- MiniMed's products are insulin pumps and continuous glucose monitors sold to patients managing diabetes.
- Because the products previously reported inside Medtronic, the debut quarter came with no stand-alone earnings history and initial guidance set without a public track record.
- The guidance raise sets the first public baseline the street can use to model MMED on its own terms and suggests management sees the positive trend extending.
A fiscal first-quarter sales beat sent MiniMed (MMED) to a record high Tuesday, and the company followed by raising its full-year guidance. The quarter was MiniMed's first as an independent public company after the spinoff from Medtronic (MDT) closed in March, giving the tape its earliest read on how the diabetes device business performs outside the parent's structure.
MiniMed's products are insulin pumps and continuous glucose monitors, sold to patients managing diabetes. Those product lines had lived inside Medtronic's reporting structure before the separation, which means the market came into MiniMed's debut quarter without any stand-alone earnings history to work from. The absence of a prior comparable quarter also means the initial guidance was set without the benefit of a public track record. Management's decision to raise that guidance after the first-quarter beat sets the first public baseline the street can use to model MMED on its own terms.
The beat-and-raise in a debut quarter removes one of the cleaner objections an investor might hold against a newly spun company, which is that first-quarter results can look flattering because transition costs have not yet fully hit the books. A guidance hike suggests management sees the positive trend extending past the initial period.
Medtronic completed the spinoff in March, meaning the fiscal first quarter reported Tuesday was MiniMed's first full three-month stretch running its own supply chain and overhead without parent company support. A sales result strong enough to lift the annual outlook under those conditions is the kind of operational signal the tape tends to reward with a move to new highs.
What to watch next is the second quarterly report, which will mark MiniMed's first multi-period read as a public company and the first test of whether the full-year guidance raised Tuesday holds.
Related reading
Filed by the newsroom of MarketPR on September 1, 2026. Source: investors.com. Indicative figures are not investment advice.